Rowlandmiller & PARTNERS.ADV Acquires New Position in Humacyte, Inc. (NASDAQ:HUMA)

Rowlandmiller & PARTNERS.ADV acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,500 shares of the company’s stock, valued at approximately $159,000.

Several other institutional investors and hedge funds have also modified their holdings of HUMA. Private Advisor Group LLC grew its holdings in shares of Humacyte by 60.7% during the 4th quarter. Private Advisor Group LLC now owns 599,700 shares of the company’s stock valued at $3,028,000 after acquiring an additional 226,590 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new position in Humacyte in the fourth quarter valued at about $130,000. Rhumbline Advisers grew its stake in Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after purchasing an additional 5,005 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in Humacyte in the fourth quarter valued at about $50,000. Finally, LJI Wealth Management LLC bought a new stake in shares of Humacyte in the 4th quarter valued at approximately $934,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HUMA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Benchmark boosted their target price on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte presently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Trading Down 5.5 %

NASDAQ HUMA opened at $3.55 on Monday. The company has a fifty day simple moving average of $4.42 and a 200 day simple moving average of $5.09. The company has a market cap of $446.17 million, a P/E ratio of -2.65 and a beta of 1.30. Humacyte, Inc. has a 1 year low of $2.81 and a 1 year high of $9.97.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.